A new era of oral agents for MDR pathogens: PK-PD considerations
Navaneeth Narayanan (Rutgers) navan12@pharmacy.rutgers.edu
Site-specific PK-PD of antimicrobials: from ELF to CNS
Keith Rodvold (U Chicago) kar@uic.edu
Defining the optimal dose through innovative pre-clinical PK-PD models and framework (Keynote)
Sujata Bhavani (ICPD) sbhavnani@icpd.com
From target to therapeutic: Early PK considerations in antimicrobial drug development (Keynote)
Alex Lepak (U of Wisconsin) ajlepak@medicine.wisc.edu
Microbiomes as Reservoirs, Catalysts, and Solutions for AMR
Michael Woodworth (Emory University) michael.holmes.woodworth@emory.edu
Healthy microbes protecting patients from AMR emergence
Mary Hayden (Rush Univ.) mhayden@rush.edu
Approach to understanding AMR emergence in microbiomes
Ashlee Earl, PhD (Broad Institute) aearl@broadinstitute.org
Harnessing the metagenomes for drug discovery
Cesar de la Fuente (U Penn):cfuente@pennmedicine.upenn.edu Assistant: bjianing@upenn.edu
Genomics of AMR: Past, Present, and Future (Keynote)
Expert Symposium A: Microbiomes as Reservoirs, Catalysts, and Solutions for AMR